iROP DL for Retinopathy of Prematurity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a tool called iROP DL (Imaging and Informatics in Retinopathy of Prematurity Deep Learning) to determine if it helps doctors diagnose retinopathy of prematurity (ROP) more accurately in premature babies. ROP can affect vision, and the trial compares doctors' ability to identify disease stages with and without the iROP DL tool. Licensed ophthalmologists interested in improving their diagnostic skills with this new technology can participate. Participants must be board-certified ophthalmologists in the U.S., agree to the study terms, and complete specific training. As an unphased trial, this study offers a unique opportunity for ophthalmologists to enhance their diagnostic skills with cutting-edge technology.
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What prior data suggests that the i-ROP DL is safe for diagnosing retinopathy of prematurity?
Research has shown that the iROP DL system, a tool using advanced computer technology, is generally safe for diagnosing retinopathy of prematurity (ROP). Studies have found that this technology accurately detects different stages of ROP without causing harm. For instance, one study noted that the iROP DL system effectively identified both those with and without the disease.
These findings suggest that the system is safe for patients. Since the iROP DL is used for diagnosis and is not a drug or surgery, the risks remain very low. The main goal is to improve the accuracy of diagnosing ROP, which is crucial for timely treatment and preventing vision loss in babies.12345Why are researchers excited about this trial?
Most treatments for Retinopathy of Prematurity (ROP) involve laser therapy or injections of medications like anti-VEGF agents. However, the iROP DL approach is different because it uses artificial intelligence to provide a Vascular Severity Score based on retinal images. This offers a non-invasive, rapid, and potentially more precise way to assess the severity of ROP. Researchers are excited because this could lead to earlier and more accurate interventions, reducing the risk of vision loss in premature infants.
What evidence suggests that the i-ROP DL is effective for diagnosing retinopathy of prematurity?
Research has shown that the iROP DL system, a tool using advanced computer technology, can effectively diagnose retinopathy of prematurity (ROP). In past studies, this system accurately identified which cases require treatment and which do not. By analyzing eye images, it predicts ROP severity, aiding doctors in decision-making before the condition worsens. Studies have also found that systems like iROP DL learn quickly and accurately identify ROP cases. Overall, the iROP DL system shows promise in improving ROP diagnosis and treatment.23567
Who Is on the Research Team?
John P Campbell, MD/MPH
Principal Investigator
Oregon Health and Science University
Are You a Good Fit for This Trial?
This trial is for U.S. board-eligible or certified ophthalmologists who have signed consent forms, completed training on the study protocol and software, and agreed to participate in a reader study. It's focused on improving diagnosis of Retinopathy of Prematurity (ROP) using an AI system.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Reading Process
Ophthalmologists perform two reads on all cases, first without and then with the aid of the i-ROP DL, separated by a memory washout period
Follow-up
Participants are monitored for safety and effectiveness after the reading process
What Are the Treatments Tested in This Trial?
Interventions
- iROP DL
iROP DL is already approved in United States for the following indications:
- Detection of more-than-mild retinopathy of prematurity (ROP)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Siloam Vision
Lead Sponsor
National Eye Institute (NEI)
Collaborator